Astera Labs, Inc. $ALAB Position Raised by Pictet Asset Management Holding SA

by · The Cerbat Gem

Pictet Asset Management Holding SA grew its position in shares of Astera Labs, Inc. (NASDAQ:ALAB – Free Report) by 29.7% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 108,340 shares of the company’s stock after acquiring an additional 24,832 shares during the quarter. Pictet Asset Management Holding SA’s holdings in Astera Labs were worth $38,566,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the business. Keating Financial Advisory Services Inc. acquired a new stake in shares of Astera Labs in the second quarter valued at approximately $25,000. Archer Investment Corp bought a new stake in shares of Astera Labs in the second quarter worth $30,000. Transamerica Financial Advisors LLC bought a new stake in shares of Astera Labs in the second quarter worth $35,000. Continuum Advisory LLC bought a new stake in shares of Astera Labs in the second quarter worth $37,000. Finally, GK Wealth Management LLC acquired a new position in Astera Labs during the third quarter worth $29,000. 60.47% of the stock is owned by institutional investors.

Astera Labs Stock Performance

Shares of NASDAQ ALAB opened at $216.18 on Wednesday. The stock has a 50 day moving average price of $297.39 and a 200 day moving average price of $256.20. The stock has a market capitalization of $37.78 billion, a PE ratio of 86.13 and a beta of 3.86. Astera Labs, Inc. has a 52 week low of $97.89 and a 52 week high of $499.48.

Astera Labs (NASDAQ:ALAB – Get Free Report) last posted its quarterly earnings results on Tuesday, November 3rd. The company reported $1.32 earnings per share for the quarter, topping the consensus estimate of $1.19 by $0.13. Astera Labs had a return on equity of 25.35% and a net margin of 29.64%. The firm had revenue of $584.90 million for the quarter, compared to analyst estimates of $550.78 million. During the same quarter in the previous year, the firm earned $0.49 EPS. The business’s quarterly revenue was up 153.6% on a year-over-year basis. As a group, research analysts forecast that Astera Labs, Inc. will post 2.99 EPS for the current year.

Trending Headlines about Astera Labs

Here are the key news stories impacting Astera Labs this week:

  • Positive Sentiment: Astera’s strong third-quarter results and outlook, alongside increasing sales of higher-value Scorpio switches, underpin the growth case. A recent report cited $585 million in Q3 revenue and $740 million midpoint guidance for Q4. Article: Astera Labs Is Increasing Their Revenue Per Accelerator
  • Positive Sentiment: Shares rallied 14% in the prior session amid a technology-stock surge, signaling potential support from stronger sector sentiment. Article: Astera Labs rallies 14% on tech stock surge
  • Neutral Sentiment: Astera will participate in the BMO Technology and Innovation Leaders Conference on November 12. The event could provide a venue for updates, but no new business announcement was included. Article: Astera Labs Announces Upcoming Financial Conference Participation
  • Negative Sentiment: ETFs were net sellers of $80.2 million in ALAB on November 6, pointing to institutional outflow pressure. Article: ETFs Are Net Sellers of Astera Labs
  • Negative Sentiment: Northland Securities lowered several 2027 quarterly EPS estimates and cut its FY2027 forecast to $4.79 from $5.43. It retained an Outperform rating and $315 target, while raising estimates for FY2026 and Q1 2027—making the revisions mixed overall.
  • Negative Sentiment: A director disclosed sales totaling about 12,499 shares under a prearranged Rule 10b5-1 plan, which may concern investors despite the planned nature of the transactions. SEC Form 4 filing

Analyst Ratings Changes

A number of research firms recently weighed in on ALAB. Northland Securities raised shares of Astera Labs from a “market perform” rating to an “outperform” rating and set a $315.00 target price for the company in a research report on Wednesday, November 4th. UBS Group lowered their price target on shares of Astera Labs from $300.00 to $290.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 4th. TD Cowen cut their price target on shares of Astera Labs from $300.00 to $225.00 and set a “hold” rating on the stock in a research report on Wednesday, November 4th. Zacks Research cut shares of Astera Labs from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 5th. Finally, Weiss Ratings downgraded shares of Astera Labs from a “buy (b-)” rating to a “hold (c)” rating in a research note on Friday, October 23rd. Thirteen research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. According to data from MarketBeat, Astera Labs has an average rating of “Moderate Buy” and an average target price of $320.85.

Get Our Latest Analysis on Astera Labs

Insider Buying and Selling

In related news, COO Sanjay Gajendra sold 90,630 shares of the firm’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $340.35, for a total value of $30,845,920.50. Following the completion of the transaction, the chief operating officer directly owned 1,119,038 shares of the company’s stock, valued at approximately $380,864,583.30. This trade represents a 7.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Manuel Alba sold 183,000 shares of the firm’s stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $280.13, for a total transaction of $51,263,790.00. Following the completion of the transaction, the director directly owned 253,863 shares of the company’s stock, valued at $71,114,642.19. This represents a 41.89% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 408,558 shares of company stock worth $126,050,884 in the last quarter. 10.40% of the stock is owned by company insiders.

About Astera Labs

(Free Report)

Astera Labs, Inc. is a fabless semiconductor company that develops connectivity solutions for cloud and artificial intelligence infrastructure. Its products are designed to help move data among processors, accelerators, memory and other components in high-performance computing systems. The company’s portfolio includes Aries PCIe and CXL retimers, Taurus Ethernet smart cable modules, Scorpio fabric switches and Leo CXL memory connectivity controllers. Astera Labs also offers software tools to help customers configure and monitor its connectivity products.

Featured Articles

Want to see what other hedge funds are holding ALAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astera Labs, Inc. (NASDAQ:ALAB – Free Report).